It might be necessary for patients with atrial fibrillation (AF) to temporarily interrupt their oral anticoagulation, for example when undergoing a surgical procedure. In the case of warfarin, this may result in an INR that is subtherapeutic for some days after re-initiation, which may lead to an increase in thromboembolic events. For DOAC this is different as patients on these drugs attain therapeutic OAC as soon as the drug is restarted, which may result in a lower risk of adverse events.
The study, presented by Dr Malini Madhavan (Mayo Clinic, USA), aimed to describe the basic characteristics of patients with temporary interruption and characteristics of temporary interruptions, to study TTR before and after a temporary interruption of warfarin, and to compare the outcome events after temporary interruption of warfarin vs DOAC. They used data from 9,749 patients aged 18 and over with electrocardiogram (ECG) evidence of AF enrolled in the multicentre ORBIT-AF registry. Temporary interruption of oral anticoagulant was defined as interruption for a procedure followed by re-initiation of the same drug. At least 1 temporary interruption occurred in 2,166 patients on warfarin and 269 patients on DOAC (of which rivaroxaban n=26 and dabigatran n=243).
Patients on warfarin had a total of 3,022 interruptions. The TTR was significantly lower than before temporary interruption of warfarin. At 3 months, the percentage time of sub-therapeutic INR was 15.9% (prior to temporary interruption) vs 17.3% after temporary interruption (P<0.0001). At 6 months, this was 15.9% vs 18.2%, respectively (P<0.0001). Patients who used a DOAC had a total of 329 interruptions with 52 patients having >1 interruption. Patients who used warfarin had a higher incidence of the composite endpoint of cardiovascular death, stroke/transient ischaemic attack, myocardial infarction, or major bleeding when compared with patients using a DOAC (see Table).
Table: Outcomes after temporary interruption of warfarin vs DOAC [1]

CV, cardiovascular; CNS, central nervous system; DOAC, direct oral anticoagulant; MI, myocardial infraction; TIA, transient ischaemic attack.
1. Madhavan M, et al. Abstract 1267-267. ACC 2019, 16-18 March, New Orleans, USA.
Posted on
Previous Article
« DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups Next Article
Unplanned hospital readmission is common after congenital cardiac surgery »
« DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups Next Article
Unplanned hospital readmission is common after congenital cardiac surgery »
Table of Contents: ACC 2019
Featured articles
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Substantial impact of temporary interruptions of warfarin versus DOAC
Smartwatch can detect atrial fibrillation with high degree of accuracy
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Frequent use of beta-blocker after HFpEF hospitalisations in elderly patients without compelling indications
High 5-year survival rates for older HF patients without initial severe comorbidity
Pulmonary Arterial Hypertension and Venous Thromboembolism
Interventional Cardiology
Vascular Medicine
Lower rates stroke/SE with DOACs in frail non-valvular AF patients
Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry
Convincing evidence of the role of icosapent in reducing subsequent CV events
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com